View all cases
UPC APP 17607/2025
EP4183412 Unitary patent · RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME
- Case details
- StatusWithdrawnActionProcedural applicationCategoryWithdrawal applications
- Parties
- Claimants
- Pfizer Inc.Operating co.
- Pfizer Europe MA EEIGOperating co.
- Pfizer B.V.Operating co.
- Pfizer S.A.Operating co.
- Pfizer Manufacturing Belgium NVOperating co.
- Pfizer Service Company S.R.L.Operating co.
- Pfizer Pharma GmbHOperating co.
- Pfizer LimitedOperating co.
Representatives- Gareth Williams-Marks & Clerk LLP
Respondents- GlaxoSmithKline Biologicals SAOperating co.
Representatives- Oliver Jan Juengst-Bird & Bird LLP
- Daniela Kinkeldey-Bird & Bird LLP
- Division
- Milan CD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- —
- First decided
- Apr 22, 2025
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Milan CD | Locked |
| Judge Andrea Postiglione | Locked |
| Judge Anna-Lena Klein | Locked |
| Judge Steen Wadskov-Hansen | Locked |
At the UPC: Pfizer Group (31 cases)·GlaxoSmithKline Biologicals SA (20 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 7 other proceedings
UPC CFI 476/2024·UPC CFI 468/2024·UPC APP 16306/2025·UPC APP 16366/2025·UPC APP 17784/2025 and 2 more
1 other defendants litigating the same or a related patent
Decisions
- 2025-04-22Application RoP 265Public
Summary: The Milan Central Division allowed Pfizer's withdrawal of both the revocation action (ACT_45928/2024) and the counterclaim for revocation (CC_60908/2024) against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV vaccine patent), with GSK's consent and without a cost decision; 60% of court fees were reimbursed to Pfizer.
Show the legal issues (3)
- Withdrawal of revocation action (R. 265 RoP)
- Court fee reimbursement
- RSV vaccine patent
Documents
- 0717E855A171C7A2E3B77E9E30038E24_en.pdf2025-04-22EN